MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.26589

Медицинская библиотека · American journal of hematology · 2022

Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.

Shah Mithun Vinod, Chhetri Rakchha, Dholakia Ruchita, Kok Chung H, Gangat Naseema, Alkhateeb Hassan B, Al-Kali Aref, Patnaik Mrinal M, Baranwal Anmol, Greipp Patricia T, He Rong, Begna Kebede H, Tiong Ing Soo, Wei Andrew H, Hiwase Devendra

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax. Median interval from t-MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7-12) months, and patients received a median of 3 (IQR 1-4) cycles. The composite complete remission (CRc) rate, median progression-free survival (PFS), and overall survival (OS) were 39.1%, 4.9 months, and 7 months, respectively. The upfront use of venetoclax and achieving CRc were associated with improved survival, whereas the presence of Chromosome 7 abnormalities was associated with an inferior survival. Neither the TP53-status nor the percent bone marrow blast predicted the likelihood of CRc or survival. Paired genetic analysis performed at venetoclax initiation and failure did not show the evidence of the selection of the TP53-mutated clone. In a propensity-matched analysis, the use of venetoclax-based regimen as the first-line therapy was associated with a superior survival compared to hypomethylating agent (HMA)-based first-line therapy (9.4 vs. 6.1 months, p = .01). We conclude that the upfront use of venetoclax with HMA improved survival, though PFS and OS remain poor. As the phenotype at diagnosis or the percent blasts did not predict outcomes, venetoclax should be studied in all t-MN phenotypes.

Для цитирования: Shah Mithun Vinod, Chhetri Rakchha, Dholakia Ruchita, Kok Chung H, Gangat Naseema, Alkhateeb Hassan B, Al-Kali Aref, Patnaik Mrinal M, Baranwal Anmol, Greipp Patricia T, He Rong, Begna Kebede H, Tiong Ing Soo, Wei Andrew H, Hiwase Devendra. Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.. American journal of hematology. 2022. DOI: 10.1002/ajh.26589.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.